Filing Flows › Co-Diagnostics (CODX) › Q4 2025
Co-Diagnostics (CODX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 31, 2026
Co-Diagnostics (CODX) reported revenue of $264K for the fourth quarter 2025 (Q4 2025), +77% from a year earlier and +82% from the quarter before.
Co-Diagnostics, Q4 2025: revenue $264K (+77% year over year), net loss $25.7M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $264K | +82% | +77% |
| Operating profit | −$26.5M | — | — |
| Net earnings | −$25.7M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $264K in Q4 2025, up 77% year over year and up 82% from the previous quarter.
Gross margin was 46.0%. Operating costs exceeded revenue by $26.5M, an operating margin of -10056.7%. The fastest-growing cost line was Other operating costs (+5262%). The quarter ended with a net loss of $25.7M, wider than the previous quarter's $5.9M loss.
Operating cash flow was −$6.2M. Non-cash charges added back $268K of depreciation and amortization and $292K of share-based compensation. Working capital and other items added $19.0M. Capital expenditures of $132K exceeded it, leaving free cash flow of −$6.3M.
Questions
What was Co-Diagnostics' revenue in the fourth quarter 2025?
Co-Diagnostics (CODX) reported revenue of $264K for the fourth quarter 2025 (Q4 2025), +77% from a year earlier and +82% from the quarter before.
Source: Co-Diagnostics 10-K on SEC EDGAR.